Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.67 |
| ▸ | MAP3K8 | P41279 | 14/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4964468 | 0.88 | EGFR (0.70) | EGFRERBB2MAP3K8 | |
| SCHEMBL14924280 | 0.88 | EGFR (0.70) | EGFRERBB2MAP3K8 | |
| SCHEMBL1896455 | 0.85 | EGFR (0.85) | EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL2840495 | 0.84 | EGFR (0.83) | EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL2843055 | 0.84 | EGFR (0.83) | EGFRERBB2 | |
| SCHEMBL1891925 | 0.84 | MAP3K8 (0.73) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4771773 | 0.84 | EGFR (0.67) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL2574073 | 0.83 | EGFR (0.85) | EGFRERBB2 | |
| SCHEMBL12641717 | 0.83 | EGFR (0.65) | EGFRERBB2MAP3K8 | |
| SCHEMBL27728124 | 0.83 | EGFR (0.69) | EGFRERBB2MAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100369919-C | Tricyclic protein kinase inhibitors | WYETH CORP (US) | 2008-02-20 | — | — | CN | disclosed |
| EP-1268487-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6608048-B2 | Treatment of cancer, polycystic kidney disease and colonic polyps in mammals | WYETH HOLDINGS | 2003-08-19 | — | — | US | disclosed |
| CN-1419559-A | Tricyclic protein kinase inhibitors | WYETH CORP (US) | 2003-05-21 | — | — | CN | disclosed |
| US-20030065180-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| EP-1268487-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072758-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065180-A1 | Tricyclic protein kinase inhibitors | PKD1, PKD2, PKN1 | EGFR 425/4885ERBB2 389/4885MAP3K8 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.